BRPI0807615A8 - Compostos de difenilmetil amônico quaternário úteis como antagonistas de receptor muscarínico - Google Patents

Compostos de difenilmetil amônico quaternário úteis como antagonistas de receptor muscarínico

Info

Publication number
BRPI0807615A8
BRPI0807615A8 BRPI0807615A BRPI0807615A BRPI0807615A8 BR PI0807615 A8 BRPI0807615 A8 BR PI0807615A8 BR PI0807615 A BRPI0807615 A BR PI0807615A BR PI0807615 A BRPI0807615 A BR PI0807615A BR PI0807615 A8 BRPI0807615 A8 BR PI0807615A8
Authority
BR
Brazil
Prior art keywords
receptor antagonists
muscarinic receptor
compounds
quaternary ammonium
compounds useful
Prior art date
Application number
BRPI0807615A
Other languages
English (en)
Inventor
Ji Yu-Hua
Husfeld Craig
Lange Christopher
Lee Rick
Mu Yongqi
Original Assignee
Theravance Inc
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39522128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0807615(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc, Theravance Biopharma R&D Ip Llc filed Critical Theravance Inc
Publication of BRPI0807615A2 publication Critical patent/BRPI0807615A2/pt
Publication of BRPI0807615A8 publication Critical patent/BRPI0807615A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSTOS DE DIFENILMETIL AMÔNIO QUATERNÁRIO ÚTEIS COMO ANTAGONISTAS DE RECEPTOR MUSCARÍNICO A invenção fornece compostos de fórmula I: (I) em forma de sal ou zwiteriônica, ou um sal farmaceuticamente aceitável destes, em que R1-6, a-e e Q são como definidos na especificação. Esses compostos são antagonistas de receptor muscarínico. A invenção também fornece composições farmacêuticas que contém tais compostos, processos para a preparação de tais compostos e métodos de uso deles, por exemplo, para tratar distúrbios pulmonares como asma e doença pulmonar construtiva crônica.
BRPI0807615A 2007-02-23 2008-02-21 Compostos de difenilmetil amônico quaternário úteis como antagonistas de receptor muscarínico BRPI0807615A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90311007P 2007-02-23 2007-02-23
PCT/US2008/002321 WO2008103426A1 (en) 2007-02-23 2008-02-21 Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists

Publications (2)

Publication Number Publication Date
BRPI0807615A2 BRPI0807615A2 (pt) 2017-10-31
BRPI0807615A8 true BRPI0807615A8 (pt) 2017-12-05

Family

ID=39522128

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807615A BRPI0807615A8 (pt) 2007-02-23 2008-02-21 Compostos de difenilmetil amônico quaternário úteis como antagonistas de receptor muscarínico

Country Status (13)

Country Link
US (4) US7834185B2 (pt)
EP (1) EP2121594B1 (pt)
JP (2) JP5528817B2 (pt)
KR (1) KR101495708B1 (pt)
CN (1) CN101616893B (pt)
AU (1) AU2008218962B2 (pt)
BR (1) BRPI0807615A8 (pt)
CA (1) CA2675942C (pt)
ES (1) ES2554646T3 (pt)
IL (1) IL199922A (pt)
MX (1) MX2009008527A (pt)
RU (1) RU2452728C2 (pt)
WO (1) WO2008103426A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2675942C (en) 2007-02-23 2016-04-12 Theravance, Inc. Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
US8202891B2 (en) 2007-04-24 2012-06-19 Theravance, Inc. Quaternary ammonium compounds useful as muscarinic receptor antagonists
JP5656288B2 (ja) * 2007-09-07 2015-01-21 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ムスカリン受容体アンタゴニストとして有用なグアジニン含有化合物
US8017617B2 (en) * 2007-12-14 2011-09-13 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
CA2716936C (en) * 2008-02-26 2018-06-05 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
UA115989C2 (uk) 2012-07-05 2018-01-25 Арвен Айлак Санайі Ве Тіджарет А.С. Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
EP3625232B1 (en) 2017-05-19 2021-06-23 Council of Scientific and Industrial Research Substituted methanopyrido [2, 1-a]isoindolones as machr modulators for treating various associated pathophysiological conditions and process for preparation thereof
AU2021266148A1 (en) 2020-04-30 2023-01-05 Idorsia Pharmaceuticals Ltd Azetidin-3-ylmethanol derivatives as CCR6 receptor modulators
WO2023057548A1 (en) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
WO2023072924A1 (en) 2021-10-26 2023-05-04 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
TW202325271A (zh) 2021-10-28 2023-07-01 瑞士商愛杜西亞製藥有限公司 Ccr6受體調節劑

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US903110A (en) 1908-05-23 1908-11-03 Us Electric Signal Company Track-switch.
US4002766A (en) 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated Antiarrhythmia methods
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5070087A (en) 1989-05-08 1991-12-03 A. H. Robins Company, Incorporated Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents
GB8928042D0 (en) * 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
DE60021282T2 (de) 1999-12-07 2006-05-18 Theravance, Inc., South San Francisco Carbamat-derivate als muscarin-rezeptor antonisten
EP1302458A4 (en) 2000-07-11 2005-10-19 Banyu Pharma Co Ltd ESTERDERIVATE
PT1461306E (pt) 2001-10-26 2009-04-01 Pharmacia & Upjohn Co Llc Compostos de amónio quaternário
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
TW200412945A (en) * 2002-10-25 2004-08-01 Upjohn Co Quaternary ammonium compounds
TWI295669B (en) * 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
JP4767842B2 (ja) * 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
TW200510298A (en) * 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
PE20050231A1 (es) 2003-06-24 2005-05-20 Novartis Ag Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
PE20050861A1 (es) * 2003-12-03 2005-12-10 Glaxo Group Ltd Derivados de sales ciclicas de amonio cuaternario como antagonistas del receptor muscarinico de acetilcolina
JP2007528418A (ja) 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なジフェニルメチル化合物
EP1749012A4 (en) * 2004-05-28 2009-07-29 Glaxo Group Ltd ANTAGONISTS OF MUSCARIN ACETYLCHOLIN RECEPTOR
JP2008525357A (ja) * 2004-12-23 2008-07-17 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 抗ムスカリン活性を有するアゾール誘導体
GB0428418D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0428416D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
WO2007018508A1 (en) * 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
WO2007022351A2 (en) * 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
CA2675942C (en) 2007-02-23 2016-04-12 Theravance, Inc. Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
US8202891B2 (en) * 2007-04-24 2012-06-19 Theravance, Inc. Quaternary ammonium compounds useful as muscarinic receptor antagonists
JP5656288B2 (ja) * 2007-09-07 2015-01-21 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ムスカリン受容体アンタゴニストとして有用なグアジニン含有化合物
US8017617B2 (en) 2007-12-14 2011-09-13 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists

Also Published As

Publication number Publication date
KR101495708B1 (ko) 2015-02-25
WO2008103426A1 (en) 2008-08-28
RU2452728C2 (ru) 2012-06-10
CA2675942A1 (en) 2008-02-28
EP2121594A1 (en) 2009-11-25
CN101616893A (zh) 2009-12-30
US20110021787A1 (en) 2011-01-27
US7834185B2 (en) 2010-11-16
JP2014098031A (ja) 2014-05-29
RU2009135389A (ru) 2011-03-27
US20140051864A1 (en) 2014-02-20
US20080207736A1 (en) 2008-08-28
KR20090117948A (ko) 2009-11-16
JP2010519299A (ja) 2010-06-03
CA2675942C (en) 2016-04-12
US8378121B2 (en) 2013-02-19
US8592453B2 (en) 2013-11-26
IL199922A0 (en) 2010-04-15
CN101616893B (zh) 2014-01-29
ES2554646T3 (es) 2015-12-22
AU2008218962B2 (en) 2013-03-14
MX2009008527A (es) 2009-08-27
IL199922A (en) 2014-08-31
US8802856B2 (en) 2014-08-12
EP2121594B1 (en) 2015-10-21
BRPI0807615A2 (pt) 2017-10-31
JP5528817B2 (ja) 2014-06-25
AU2008218962A1 (en) 2008-08-28
US20110020231A1 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
BRPI0807615A8 (pt) Compostos de difenilmetil amônico quaternário úteis como antagonistas de receptor muscarínico
BRPI0517945A (pt) derivados de quinuclidina e seu uso como antagonistas de receptor muscarìnico m3
BRPI0719361B8 (pt) composto, composição farmacêutica, e, uso do composto
BRPI0609719B8 (pt) derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2
WO2009132202A3 (en) Macrocyclic compounds and their use as kinase inhibitors
SI2150530T1 (sl) Substituirani sulfonamidni derivati
WO2010042925A3 (en) Compositions and methods for treating alcohol use disorders, pain and other diseases
BR112013016595A2 (pt) inibidores de neprilisina
WO2011121418A9 (en) 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
BRPI0720270B8 (pt) compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida
BR112012013431A8 (pt) composto, composição farmacêutica e seu uso
WO2009016410A3 (en) Chemical compounds 831
CO6321265A2 (es) Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso
BR112014001880A2 (pt) derivados de carboxamida e ureia contendo pirazol heteroaromáticos substituídos como ligantes de receptor vaniloide
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
BR112013026202A2 (pt) composições e usos terapêuticos de inibidores quinase epsilon relacionado a ikk e quinase i de ligação a tank
BRPI0714315B8 (pt) arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende
IL204064A (en) Compounds 4-Formylphiprazine-1-Carboxamidine Efficacy as Muscarinic Receptor Antagonists
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
NO20082746L (no) Kinazoliner anvendelige som modulatorer for spenningsstyrte ionekanaler
WO2013040227A3 (en) Therapeutic compounds
WO2008045371A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
NI201000195A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3.
UA113409C2 (xx) Солі азабіциклічних діарилових ефірів та способи їх одержання або одержання їх попередників

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: THERAVANCE BIOPHARMA RANDD IP, LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]